GSK Reportedly Pulls Application For Drug Touted By Trump As Potential Treatment For Autism

UK drugmaker GSK Plc (GSK) has reportedly withdrawn its application for the drug leucovorin calcium touted by President Trump as a potential treatment for autism.

According to a report from the Wall Street Journal on Thursday, GSK asked the U.S. Food and Drug Administration to pull its application for leucovorin calcium because it doesn’t market the medicine. The company hasn’t sold the drug since 1999, the report said.  

GSK in September said it would submit an application for the drug in the treatment of cerebral folate transport deficiency following a request from the FDA. The agency approved the drug for the condition last month but not for autism.

A GSK spokesperson reportedly told the newspaper that the company never intended to sell the drug again. 

Get updates to this developing story directly on Stocktwits.